Article Summary
喻青 沈曼茹 唐鄂 黄继英 高振军.CK-18 降解片段M30和MMP-2 在慢性乙型肝炎纤维化严重程度 预测中的作用[J].现代生物医学进展英文版,2014,14(34):6650-6653.
CK-18 降解片段M30和MMP-2 在慢性乙型肝炎纤维化严重程度 预测中的作用
The Predictive Effect of SerumApoptotic Cytokeratin 18 Neoepitope M30(CK-18 M30) and Matrix Metalloproteinase 2 (MMP-2) Levels inHBeAg-negative Chronic Hepatitis B Patients with Fibrosis
  
DOI:
中文关键词: 慢性乙型肝炎  细胞角蛋白-18  基质金属蛋白酶  肝纤维化
英文关键词: Chronic hepatitis B  Cytokeratine 18 neoepitope M30  Matrix metalloproteinase 2  Liver fibrosis
基金项目:
Author NameAffiliation
YU Qing, SHEN Man-ru, TANG E, HUANG JI-ying,GAO Zhen-jun 复旦大学附属中山医院青浦分院消化科 
Hits: 795
Download times: 824
中文摘要:
      目的:探讨血清细胞角蛋白-18 裂解片段M30(CK-18 M30)和基质金属蛋白酶(MMP-2)水平对乙型肝炎e 抗原(HBeAg)阴 性慢性乙型肝炎纤维化严重程度预测的作用。方法:选取我院156 例HBeAg 阴性的慢性乙型肝炎(CHB)患者和51 例对照组。肝 组织病理学分级依据Scheuer标准。常规收集临床资料,ELISA 法检测血清CK-18 M30和MMP-2 水平。结果:本研究CHB组男 性为106 人(67.9%),女性为50人(32.1%);对照组男性为33 人(63.5%),女性为19 人(36.5%),两组间性别、年龄无统计学差异; CHB组CK-18 M30和MMP-2 显著高于对照组(P<0.001)。CK-18 M30 预测是否有显著性肝纤维化的AUC为0.863(P<0.001); 而MMP-2 预测是否有显著性肝纤维化的AUC为0.587,差异无统计学意义(P=0.064)。结论:血清CK-18 M30 和MMP-2 水平在 CHB组显著升高,CK-18 M30 可能可预测HBeAg 阴性的慢性乙型肝炎纤维化严重程度,可能具有较好的临床应用前景。
英文摘要:
      Objective:The objective of this study was to investigate the significance of cytokeratine 18 neoepitope M30 (CK-18 M30) and matrix metalloproteinase 2 (MMP-2) levels for patients with chronic hepatitisB (CHB) and fibrosis.Methods:This study included 156 CHB patients and 52 healthy controls. Scheuer scoring system was used to determine the fibrosis level in chronic hepatitis B patients. CK-18 M30 and MMP-2 levels were measured using Enzyme Linked Immunosorbent Assay (ELISA) methods.Results:The CHB group consisted of 106 (67.9%) males and 50 (32.1%) females, and the control group consisted of 33 males (63.5%) and 19 females (36.5%). In our study, the areas under the ROC curve (AUCs) of CK-18 M30 and MMP-2 for predicting significant fibrosis were 0.863 (P<0.001)and 0.587(P=0.064), respectively.Conclusion:We found that CK-18 M30 and MMP-2 levels were higher in CHB patients compared to healthy controls. CK-18 M30 may predict HBeAg-negative chronic hepatitis B patients with significant fibrosis, and the application of the marker is promising.
View Full Text   View/Add Comment  Download reader
Close